Artivion (NYSE:AORT) Lowered to “Hold” Rating by Wall Street Zen

Artivion (NYSE:AORT) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

AORT has been the subject of several other research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $58.00 price target on shares of Artivion in a research report on Monday, February 2nd. Canaccord Genuity Group cut their target price on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday. Oppenheimer reaffirmed an “outperform” rating and issued a $50.00 price objective on shares of Artivion in a research note on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, January 21st. Finally, Citizens Jmp lifted their price objective on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Artivion has an average rating of “Moderate Buy” and a consensus target price of $48.69.

Artivion Trading Down 10.9%

NYSE:AORT opened at $36.24 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.93 and a quick ratio of 2.88. The firm has a market capitalization of $1.72 billion, a P/E ratio of 181.18 and a beta of 1.59. The company’s 50-day simple moving average is $43.60 and its 200 day simple moving average is $42.79. Artivion has a one year low of $21.97 and a one year high of $48.25.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.03. The firm had revenue of $118.30 million for the quarter, compared to the consensus estimate of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.74%. The business’s quarterly revenue was up 19.2% on a year-over-year basis. As a group, analysts forecast that Artivion will post 0.37 EPS for the current fiscal year.

Insider Buying and Selling at Artivion

In other Artivion news, Director Elizabeth A. Hoff sold 4,200 shares of Artivion stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $45.10, for a total transaction of $189,420.00. Following the completion of the sale, the director directly owned 27,189 shares in the company, valued at approximately $1,226,223.90. The trade was a 13.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CAO Amy Horton sold 4,572 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $44.42, for a total value of $203,088.24. Following the sale, the chief accounting officer directly owned 130,058 shares in the company, valued at approximately $5,777,176.36. This trade represents a 3.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 128,448 shares of company stock valued at $5,793,361. Insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Artivion

Hedge funds have recently bought and sold shares of the business. Verition Fund Management LLC boosted its holdings in Artivion by 1.6% in the 3rd quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock worth $716,000 after buying an additional 274 shares during the last quarter. State of Alaska Department of Revenue boosted its position in shares of Artivion by 1.8% during the 3rd quarter. State of Alaska Department of Revenue now owns 23,294 shares of the company’s stock worth $985,000 after purchasing an additional 414 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of Artivion by 6.2% in the third quarter. PNC Financial Services Group Inc. now owns 8,232 shares of the company’s stock valued at $349,000 after buying an additional 477 shares in the last quarter. Arizona State Retirement System increased its stake in Artivion by 4.6% during the fourth quarter. Arizona State Retirement System now owns 11,235 shares of the company’s stock worth $512,000 after purchasing an additional 494 shares during the period. Finally, Van ECK Associates Corp lifted its holdings in Artivion by 19.0% during the 3rd quarter. Van ECK Associates Corp now owns 3,176 shares of the company’s stock worth $134,000 after buying an additional 506 shares in the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

More Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q4 beat — Artivion reported Q4 EPS of $0.17 versus the $0.14 consensus and revenue of $118.3M (above estimates), with quarterly revenue up ~19% year-over-year. This confirms continued top-line momentum. Read More.
• Positive Sentiment: Full-year revenue growth — GAAP revenue rose to $441.3M for FY2025 from $388.5M in FY2024, signaling sustained recovery/expansion in sales. Read More.
• Positive Sentiment: FY2026 revenue guidance modestly above street — management guided revenue to $486.0M–$504.0M (consensus ~$491.1M), which implies a midpoint slightly ahead of estimates and supports continued top-line growth. Read More.
• Neutral Sentiment: Earnings call materials/transcript posted — the full Q4 earnings call transcript and slide deck are available for detail on segment performance and cadence. Useful for investors wanting management color. Read More.
• Negative Sentiment: Analyst price-target trim — Canaccord cut its AORT price target from $51 to $48 while keeping a “buy” rating; the cut reduces near-term analyst upside and may have pressured sentiment. Read More.
• Negative Sentiment: EPS guidance unclear/omitted — the company’s release/summary lacked clear EPS guidance (the EPS figure was not provided in the guidance summary), which can create uncertainty even with revenue guidance in place. Read More.
• Negative Sentiment: Large-volume sell-off — shares moved lower on unusually high volume versus average, indicating stronger selling pressure that amplified the price reaction to mixed news. Read More.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.